Deep Vein Thrombosis

Clinical Trial Finder

Many patients with deep vein thrombosis are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study

Condition:   Venous Thromboembolism
Intervention:   Drug: Rosuvastatin
Sponsor:   Ottawa Hospital Research Institute
Not yet recruiting - verified February 2016

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Condition:   Venous Thromboembolism
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Conditions:   Deep Vein Thrombosis;   Malignant Neoplasm;   Portal Vein Thrombosis;   Pulmonary Embolism;   Renal Vein Thrombosis;   Venous Thromboembolism
Interventions:   Drug: Apixaban;   Drug: Dalteparin;   Other: Questionnaire Administration
Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

Safety and Efficacy Study of Apixaban to Prevent Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With PEG Asparaginase

Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2015

Rituximab and Belimumab for Lupus Nephritis

Condition:   Lupus Nephritis
Interventions:   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Rituximab;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Methylprednisolone;   Drug: Diphenhydramine;   Drug: Acetaminophen;   Biological: Belimumab
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
Recruiting - verified February 2016

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

Conditions:   Anemia;   Cardiovascular Disease
Interventions:   Drug: EPO;   Drug: Feraheme
Sponsors:   University of Texas Southwestern Medical Center;   AMAG Pharmaceuticals, Inc.
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis.

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified February 2016

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:   Drug: Observational
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol

Condition:   Postoperative Complications
Intervention:  
Sponsor:   University of California, Irvine
Recruiting - verified February 2016

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Conditions:   Rivaroxaban;   Cancer-associated Thrombosis;   Recurrence;   Bleeding
Intervention:   Drug: Rivaroxaban
Sponsors:   Seoul National University Hospital;   Korean Society of Hematology Thrombosis Working Party
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT

Condition:   Deep Vein Thrombosis
Interventions:   Drug: Bemiparin sodium;   Drug: Enoxaparin sodium
Sponsor:   Berlin-Chemie AG Menarini Group
Completed - verified February 2016

Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)

Conditions:   Neoplasm;   Central Venous Catheter Thrombosis
Intervention:   Drug: Rivaroxaban
Sponsor:   London Health Sciences Centre
Active, not recruiting - verified February 2016

Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement)

Conditions:   Prophylaxis, Thromboembolism, Venous;   Total Knee Replacement;   Total Hip Replacement
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Withdrawn - verified February 2016

Autologous Cell Therapy After Stroke

Condition:   Stroke
Interventions:   Biological: autologous bone marrow mononuclear cell transfusion;   Biological: marrow stromal cells;   Drug: placebo
Sponsors:   University of California, Irvine;   University of California, San Diego
Withdrawn - verified February 2016

Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome

Conditions:   Post Thrombotic Syndrome;   Deep Vein Thrombosis;   Venous Stasis Syndrome;   Venous Insufficiency;   Postphlebitic Syndrome
Intervention:   Device: VeinOPlus
Sponsors:   Stephan Moll, MD;   University of North Carolina, Chapel Hill;   VeinoPlus USA
Completed - verified February 2016

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

Condition:   HIV
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2016